Categories
ykqisdscp

Global Pharmaceutical Treatments for Mental Health Disorders Market (2020 to 2025) – Conditions are…

first_imgLocal NewsBusiness Previous articleSES Government Solutions Provides High-throughput Loopback Services to U.S. Department of DefenseNext articleEJF Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering Digital AIM Web Support Pinterest Facebook DUBLIN–(BUSINESS WIRE)–Feb 24, 2021– The “Pharmaceutical Treatments for Mental Health Disorders: Global Markets” report has been added to ResearchAndMarkets.com’s offering. This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms. Companies MentionedAbbvieAcadia Pharmaceuticals Inc.Adamis Pharmaceuticals Corp.Alkermes PlcAstrazeneca PlcBioxcel Therapeutics Inc.Boehringer Ingelheim International GmbhEli Lilly & Co.Glaxosmithkline PlcH Lundbeck A/SIntervexion TherapeuticsIntra-Cellular Therapies Inc.Ironshore PharmaceuticalsJohnson & JohnsonKempharm Inc.Minerva Neurosciences Inc.Neos Therapeutics Inc.NLS Pharmaceutical AgNoven Pharmaceuticals Inc.Orexo AbOtsuka Holdings Co. Ltd.Pear TherapeuticsPfizer Inc.Sage TherapeuticsShionogi & Co. Ltd.Specialty Pharma And BiotechsSupernus Pharmaceuticals, Inc.Takeda Pharmaceuticals Co. Ltd.Tonix Pharmaceuticals Holdings Corp.Tris Pharma Inc. Report Includes:46 data tables and 12 additional tablesAn overview of the global markets for pharmaceutical treatments for mental health disordersAnalyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growthDescription of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COVID-19 pandemic, social distancing and social isolation on the mental health conditionsA look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)Information on tele mental health software such as ReSet, Pears Somryst and Alkili’s EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disordersSnapshot of leading mental health conditions, and products in phase III development for selected psychiatric disordersAnalysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COVID-19 pandemic, social distancing and social isolation. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Depression and AnxietyMarket LandscapeSegmentation by Drug ClassSegmentation by CompanyPrevalence of DisordersDiagnosisCurrent TreatmentsSelective Serotonin Reuptake Inhibitors (SSRIs)Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)Tricyclic Antidepressants (TCAs)Monoamine Oxidase Inhibitors (MAOIs)Atypical Antipsychotics and Second-Generation Antipsychotics (SGAs)BenzodiazepinesRecent Drug DevelopmentsDrug/CompanyLate-Stage Drug Failures/WithdrawalsDrugs in Clinical Development to Treat DepressionPhase 3 Drugs in Development to Treat DepressionPhase 2 Drugs in Development to Treat DepressionDrugs in Clinical Development to Treat AnxietyPhase 3 Drugs in Development to Treat AnxietyPhase 2 Drugs in Development to Treat AnxietyAlternative ApproachesDigital TherapeuticsM&A ActivityFuture Opportunities Chapter 4 Attention Deficit Hyperactivity DisorderMarket LandscapeSegmentation by GeographySegmentation by Drug ClassSegmentation by CompanyPrevalenceDiagnosisCurrent TreatmentsRecent Drug DevelopmentsDrugs/CompaniesLate-Stage Drug Failures/WithdrawalsDrugs in Clinical Development to Treat ADHDPhase 3 Drugs in Development to Treat ADHDPhase 2 Drugs in Development to Treat ADHDAlternative ApproachesDigital TherapeuticsM&A ActivityFuture Opportunities Chapter 5 SchizophreniaMarket LandscapeSegmentation by GeographySegmentation by Drug ClassSegmentation by CompanyPrevalenceDiagnosisCurrent TreatmentsRecent Drug DevelopmentsDrugs/CompaniesLate-Stage Drug Failures/WithdrawalsDrugs in Clinical Development to Treat SchizophreniaPhase 3 Drugs in Development to Treat SchizophreniaPhase 2 Drugs in Development to Treat SchizophreniaAlternative ApproachesDigital TherapeuticsM&A ActivityFuture Opportunities Chapter 6 Substance Use DisordersMarket LandscapeSegmentation by GeographySegmentation by Drug ClassSegmentation by CompanyPrevalenceDiagnosisCurrent TreatmentsOpioid Use DisordersAlcohol Use DisordersNicotine Use DisordersRecent Drug DevelopmentsDrugs in Clinical Development to Substance Abuse DisorderPhase 3 Drugs in Development to Treat Substance Use DisordersPhase 2 Drugs in Development to Treat Substance Use DisorderAlternative ApproachesDigital TherapeuticsM&A ActivityFuture Opportunities Chapter 7 Company Profiles For more information about this report visit https://www.researchandmarkets.com/r/oqajq2 View source version on businesswire.com:https://www.businesswire.com/news/home/20210224005783/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MENTAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/24/2021 11:37 AM/DISC: 02/24/2021 11:37 AM http://www.businesswire.com/news/home/20210224005783/en Twitter WhatsApp Global Pharmaceutical Treatments for Mental Health Disorders Market (2020 to 2025) – Conditions are Likely to Rise in the Near Future Due to the Consequences of COVID-19 – ResearchAndMarkets.comcenter_img TAGS  Twitter WhatsApp By Digital AIM Web Support – April 6, 2021 Pinterest Facebooklast_img

Leave a Reply

Your email address will not be published. Required fields are marked *